Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021
Pacira BioSciences, Inc. (NASDAQ:PCRX) is set to release its third quarter financial results on November 3, 2021, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can join the call by dialing the provided numbers or accessing the webcast via the Pacira investor website. Notably, Pacira emphasizes its leadership in non-opioid pain management, particularly with its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia system, highlighting its commitment to improving patient outcomes.
- Upcoming financial results announcement for Q3 2021 may provide insights into revenue and growth.
- Pacira is recognized as an industry leader in non-opioid pain management.
- None.
PARSIPPANY, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday, November 3, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
To participate in the conference call, dial 1-877-845-0779 and provide the passcode 5562638. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.
For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 5562638. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
When will Pacira BioSciences announce its Q3 2021 financial results?
What time is the Pacira BioSciences conference call scheduled?
How can I participate in the Pacira BioSciences conference call?
What key products does Pacira BioSciences focus on?
